Statins for the prevention of cardiovascular events

National Institute for Health and Clinical Excellence
Record ID 32006000062
Authors' objectives:

This guidance assesses statins for the prevention of cardiovascular events.

Authors' recomendations: 1 Guidance This guidance relates only to the initiation of statin therapy in adults with clinical evidence of cardiovascular disease (CVD) and in adults considered to be at risk of CVD. It assumes that other strategies for managing CVD risk are being appropriately considered when initiating statin therapy. The guidance does not include specific advice for genetic dyslipidaemias (for example, familial hypercholesterolaemia). The guidance relates only to the use of statins within their licensed indications. A clinical guideline on cardiovascular risk assessment is currently in development (expected date of publication: September 2007). This guidance should be read in the context of the clinical guideline when it is available. 1.1 Statin therapy is recommended for adults with clinical evidence of CVD. 1.2 Statin therapy is recommended as part of the management strategy for the primary prevention of CVD for adults who have a 20% or greater 10-year risk of developing CVD. This level of CVD risk should be estimated using an appropriate risk calculator, or by clinical assessment for people for whom an appropriate risk calculator is not available (for example, older people, people with diabetes or people in high-risk ethnic groups). 1.3 Within the recommendations outlined in Section 1.1 and Section 1.2, the decision whether to initiate statin therapy should be made after an informed discussion between the responsible clinician and the individual about the risks and benefits of statin treatment, and taking into account additional factors such as comorbidities and life expectancy. 1.4 When the decision has been made to prescribe a statin, it is recommended that therapy should usually be initiated with a drug with a low acquisition cost (taking into account required daily dose and product price per dose).
Authors' methods: Review
Project Status: Completed
Year Published: 2006
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England
MeSH Terms
  • Cardiovascular Diseases
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
Organisation Name: National Institute for Health and Care Excellence
Contact Address: MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
Contact Email:
Copyright: National Institute for Health and Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.